Funding The Future: Accelerating The Long Walk To Innovation

Good ideas must be paired with good people

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.  

accelerator people
Its the people involved in the deal that create company acceleration • Source: Shutterstock

Investment in ideas and new science takes research, and often faith to make innovation work. What may be a good idea on paper may not be scalable, or even answer an unmet need for patients. Entering the innovation arena before seed funding and venture capital are companies such as Deep Science Ventures and Oxford Science Enterprises, each taking its own approach to accelerating innovation.

Deep Science Ventures was borne from the philosophy of co-founders Mark Hammond and Dominic Falcão, both previously from Imperial College...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Science

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.